Market Overview
The Global
Neurological Disorder Drugs Market is expected to reach a value of
USD 66.4 billion by the end of 2024, and it is further anticipated to reach a market value of
USD 103.8 billion by 2033 at a
CAGR of 5.1%.
Neurological diseases occur from dysfunction in the brain or nervous system, leading to physical or psychological symptoms, as they include various medications like antipsychotics, antiepileptics, anticholinergics, & analgesics, customized to the specific condition. These drugs help manage symptoms and enhance the quality of life, and corticosteroids are commonly utilized for minimizing inflammation in conditions like multiple sclerosis.
Rising awareness about early
disease diagnosis, driven by campaigns from government agencies and private organizations, coupled with the anticipated market entry of efficient drugs supported by a robust drug pipeline, is expected to propel the growth of the neurological disorder drugs market.
For example, a 2018 report by the Pharmaceutical Research and Manufacturers of America (PhRMA) highlighted that U.S. biopharmaceutical companies are developing 537 medicines for various neurological conditions. These include 95 for brain tumors, 46 for chronic pain, 92 for Alzheimer’s disease, and 30 targeting conditions such as multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson’s disease.
Additionally, major players are securing regulatory approvals to strengthen their market presence. In 2017, the U.S. FDA approved Neurocrine Biosciences’ Ingrezza (valbenazine), the first drug for treating tardive dyskinesia in adults.
Key Takeaways
- The Global Neurological Disorder Drugs Market is expected to grow by 37.4 billion, at a CAGR of 5.1% during the forecasted period.
- By Drug Type, antipsychotics are expected to drive the market in 2024 & are anticipated to dominate throughout the forecasted period.
- By Disease Type, epilepsy is a major disease, which is expected to drive the market in 2024.
- By Distribution Channel, hospital pharmacies are anticipated to lead and drive the overall market in 2024.
- North America is expected to hold a 46.5% share of revenue in the Global Neurological Disorder Drugs Market in 2024.
- Some of the use cases of neurological disorder drugs include disease modification, symptom management, and more
Use Cases
- Symptom Management: Neurological disorder drugs are used to manage numerous symptoms associated with conditions like epilepsy, Parkinson's disease, & multiple sclerosis. Like, antiepileptic medications help control seizures in epilepsy patients, while dopamine agonists are utilized to reduce motor symptoms in Parkinson's disease.
- Disease Modification: Some neurological disorder drugs focus on modifying the progression of the underlying condition such as disease-modifying therapies in multiple sclerosis, including interferons and monoclonal antibodies, work to minimize relapses & slow down disease progression.
- Quality of Life Improvement: By effectively managing symptoms & disease progression, neurological disorder drugs can majorly improve patients' quality of life. Drugs like antidepressants & anxiolytics may be prescribed to address mood disorders commonly associated with neurological conditions, enhancing overall well-being.
- Preventative Measures: In certain cases, neurological disorder drugs are utilized preventively to minimize the likelihood of symptom exacerbation or disease progression. For instance, antiepileptic medications may be prescribed prophylactically to save seizures in high-risk individuals or those with a history of frequent seizures.
Market Dynamic
The market for neurological disorder drugs is experiencing growth due to many factors. With an aging population, there's a growth in neurological problems like stroke and migraine, impacting people across many countries. Countries like France, Sweden, & Greece see high rates of cerebrovascular illness among middle and elderly aged people. In addition, the growth in healthcare expenditure & government initiatives to improve healthcare infrastructure contribute to market expansion.
Also, growth in awareness campaigns & the introduction of new and efficient drugs drive market growth. However, the market growth experiences challenges due to the high expenses of R&D, inadequate healthcare infrastructure in developing nations, shortage of skilled professionals, along with product recalls, and strict government regulations.
Driving Factors
Neurological disorders such as
Alzheimer's, Parkinson's, Epilepsy and Multiple Sclerosis have become an increasing trend, making the market for neurological disorder drugs even more dynamic than before. An aging global population compounds this demand as these conditions disproportionately impact older individuals. Advancements in diagnostic technology enable earlier and more accurate detection, further fuelling demand for effective treatments.
Public awareness campaigns and government initiatives for
mental health and neurological care help boost market expansion. Furthermore, rising healthcare expenditure and insurance coverage in both developed and developing nations have increased patient access to medications, leading to steady market expansion for neurological disorder drugs.
Trending Factors
Biopharmaceutical companies are adopting cutting edge technologies such as
genomics, proteomics and artificial intelligence in their quest to develop neurological disorder treatments. Innovative techniques like gene therapies, RNA based treatments and disease modifying drugs are increasingly utilized. Companies are emphasizing precision medicine, tailoring treatments to individual genetic profiles for optimal outcomes.
Biologics and biosimilars have revolutionized the market by offering more focused solutions for complex conditions. Collaborations among academic institutions, startups, and established pharmaceutical firms have led to groundbreaking research. With numerous clinical trials currently under way and regulatory approvals of innovative medications on the rise, neurological disorder drugs market is poised for exponential growth.
Restraining Factors
Restraint The high cost of neurological disorder drugs remains an insurmountable obstacle, making treatment unattainable for many in low income areas. Long and cumbersome regulatory approval processes add a further financial burden for manufacturers. Neurological conditions often necessitate extensive research and clinical trials due to their complex pathophysiologie, increasing development costs significantly. Patent expirations presents generic competition which erodes profitability for existing drugs.
Furthermore, treatment efficacy varies considerably among patients making it challenging to create universally effective solutions. All these factors combine to limit the growth of the neurological disorder drugs market despite an increasing demand for innovative treatments.
Opportunities
Emerging markets present ample opportunity for the neurological disorder drugs industry due to increasing healthcare investments and greater awareness of neurological conditions. Countries like China, India and Brazil with rising middle class populations and expanded insurance coverage benefit from greater patient access to advanced therapies. Local manufacturing initiatives to promote generic drug production reduce costs, making treatments more accessible.
Telemedicine and digital health platforms are also making strides forward, providing remote areas with easier diagnosis and management. Collaborations between multinational and local pharmaceutical companies allow market penetration and growth factors which make emerging markets an opportune target for neurological drug manufacturers.
Research Scope and Analysis
By Drug Type
Antipsychotics are expected to drive the neurological disorder drugs market in 2024, as these are medications majorly used to manage symptoms of neurological disorders like schizophrenia & bipolar disorder. They work by changing the balance of certain chemicals in the brain, mainly dopamine.
By doing so, antipsychotics help minimize hallucinations, delusions, & other symptoms associated with these conditions. These drugs can be categorized into typical & atypical antipsychotics, each with varying side effects & effectiveness.
Further, Antiepileptic drugs are anticipated to show steady growth in coming years, as these are medications used to treat epilepsy &other neurological conditions characterized by seizures. They work by stabilizing electrical activity in the brain, helping to prevent or minimize seizure occurrences.
By Disease Type
Epilepsy is a major disease, expected to drive the neurological disorder drug market in 2024, as it is characterized by recurrent seizures due to abnormal electrical activity in the brain. These seizures can differ in type and intensity, affecting people differently. Neurological disorder drugs, like antiepileptic medications, are commonly used to manage epilepsy.
These drugs work by fixing electrical signals in the brain, reducing the frequency & severity of seizures. Alongside medication, other treatments like lifestyle modifications & sometimes surgery may be recommended to help control seizures & enhance the quality of life for individuals living with epilepsy.
Further, Parkinson's disease is anticipated to have significant growth in coming years, as it is a neurological disorder that affects movement, creating tremors, stiffness, and difficulty with coordination and balance. Neurological disorder drugs for Parkinson's particularly focus on managing symptoms by increasing dopamine levels in the brain.
By Distribution Channel
Hospital pharmacies play an important role in delivering neurological disorder drugs and are expected to lead the market in 2024 and persist its dominance throughout the forecasted period by ensuring their safe procurement, storage, and distribution within healthcare facilities, as pharmacists work closely with healthcare teams to verify prescriptions, educate patients on medication use, and monitor for potential drug interactions or adverse effects.
They also partner with physicians to adjust medication regimens as required to optimize treatment outcomes for patients with neurological disorders, establishing that they receive the appropriate medications in a timely & effective manner.
Further, retail pharmacies are expected to show steady growth, as they serve as accessible points of care for individuals managing neurological disorders by dispensing prescribed medications, delivering counseling on proper medication use, & providing support and guidance to patients & caregivers to optimize treatment adherence and outcomes.
The Neurological Disorder Drugs Market Report is segmented on the basis of the following:
By Drug Type
- Antipsychotic
- Antiepileptic
- Anticholinergic
- Analgesics
- Hypnotic & Sedative
- Anticoagulants
- Antihypertensive
By Disease Type
- Epilepsy
- Parkinson’s disease
- Alzheimer’s disease
- Cerebrovascular disease
- Multiple Sclerosis
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Analysis
North America is anticipated to have a leading position in the global market for neurological disorder drugs of
46.5% in 2024 and is anticipated to show its dominance throughout the forecast period, which is due to several factors, including the major presence of key pharmaceutical companies in the region. Moreover, the approval & introduction of innovative drugs by these companies further expand North America's market position.
Also, the region's better healthcare infrastructure & advanced research facilities contribute to its dominance. In addition, favorable regulatory frameworks & supportive government initiatives facilitate shift approvals & commercialization of new drugs, boosting the market's growth prospects.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The global market for neurological disorder drugs is characterized by strong competition among pharmaceutical companies looking to develop innovative treatments, as key players in the market constantly invest in R&D to introduce new drugs for different neurological conditions like Alzheimer's disease, Parkinson's disease, & multiple sclerosis. In addition, partnerships, mergers, and acquisitions play a major role in shaping the competitive landscape, as players focus on expanding their product portfolios & market presence in this rapidly evolving sector.
Some of the prominent players in the global Neurological Disorder Drugs Market are
- Merck kGaA
- Sanofi
- Pfizer Inc
- Cipla Inc
- Abbott
- Biocon
- Sumitomo Corp
- AstraZeneca
- Johnson & Johnson Pvt Ltd
- Novo Nordisk A/S
- Other Key Players
Recent Developments
- In January 2024, AbbVie has launched PRODUODOPA in the European Union, developed for advanced Parkinson's disease with severe motor fluctuations & hyperkinesia or dyskinesia. Also, it's the first subcutaneous 24-hour levodopa infusion, providing constant delivery to extend well-controlled symptom periods for patients.
- In August 2023, Neurocrine Biosciences, Inc. unveiled the U.S. FDA approval for INGREZZA capsules for the treatment of adults with chorea associated with Huntington's disease, as it is the only selective vesicular monoamine transporter inhibitor that provides an efficient starting dosage that can be adjusted by a patient's healthcare provider based on response & tolerability, with no complex titration.
- In June 2023, UCB announced that the company received FDA approval for RYSTIGGO in treating generalized myasthenia gravis in adults positive for the anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. Further, its subcutaneous infusion is a monoclonal antibody targeting the neonatal Fc receptor, minimizing circulating IgG.
- In March 2023, Acadia Pharmaceuticals Inc. unveiled that the US FDA approved DAYBUE for the treatment of Rett syndrome in adult & pediatric patients of two years of age and older, as it is the first & only drug approved for the treatment of Rett syndrome.
- In February 2023, Pfizer Inc. unveiled its findings in The Lancet Neurology from a Phase 3 trial of Zavegepant, a nasal spray for acute migraine treatment, which indicated that a single 10 mg dose was superior to a placebo for pain freedom & relief from the most bothersome symptom at two hours post-dose, a and provided rapid pain relief lasting up to 48 hours as well as better tolerated with no serious adverse events.
Report Details
| Report Characteristics |
| Market Size (2024) |
66.4 Bn |
| Forecast Value (2033) |
USD 103.8 Bn |
| CAGR (2023-2033) |
5.1% |
| Historical Data |
2018 – 2023 |
| Forecast Data |
2024 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Drug Type (Antipsychotic, Antiepileptic,
Anticholinergic, Analgesics, Hypnotic & Sedative,
Anticoagulants, Antihypertensive), By Disease Type
(Epilepsy, Parkinson’s disease, Alzheimer’s disease,
Cerebrovascular disease, Multiple Sclerosis, and
Others), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, and Online
Pharmacies) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Merck kGaA, Sanofi, Pfizer Inc, Cipla Inc, Abbott,
Biocon, Sumitomo Corp, AstraZeneca, Johnson &
Johnson Pvt Ltd, Novo Nordisk A/S, and Other Key
Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The Global Neurological Disorder Drugs Market size is estimated to have a value of USD 66.4 billion in
2024 and is expected to reach USD 103.8 billion by the end of 2033.
North America is expected to have the largest market share in the Global Neurological Disorder Drugs
Market with a share of about 46.5% in 2024.
Some of the major key players in the Global Neurological Disorder Drugs Market are Merck kGaA,
Sanofi, Pfizer Inc, and many others.
The market is growing at a CAGR of 5.1 percent over the forecasted period.